| Genomic Medicine |
1 |
1 |
| Epidermal Growth Factor Receptor |
0 |
0.88 |
| Lung Cancer |
0 |
0.72 |
| EGFR Inhibitor |
0 |
0.65 |
| Biologic Therapy |
0 |
0.53 |
| Chemotherapy |
0 |
0.37 |
| Non-Small Cell Lung Cancer |
0 |
0.99 |
| Toxicology |
0 |
0.28 |
| Antineoplastic Drug |
0 |
0.24 |
| Tyrosine Kinase Inhibitor |
0 |
0.22 |
| Vascular Endothelial Growth Factor |
0 |
0.21 |
| VEGF Inhibitor |
0 |
0.21 |
| Monoclonal Antibody |
0 |
0.13 |
| Clinical Guidelines |
0 |
0.11 |
| Cancer |
0 |
0.08 |
| Small Cell Lung Cancer |
0 |
0.08 |
| Targeted Cancer Therapy |
0 |
0.08 |
| Clinical Research |
0 |
0.05 |
| Quality of Life |
0 |
0.05 |
| Receptors |
0 |
0.05 |
| Angiogenesis |
0 |
0.03 |
| Canada |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Hypertension |
0 |
0.03 |
| Immunotherapy |
0 |
0.03 |
| Lung |
0 |
0.03 |
| Platinum |
0 |
0.03 |
| Tumor |
0 |
0.03 |
| Tyrosine Kinase |
0 |
0.03 |